This article is more than 5 years old. Information may no longer be current.

Imprimis reports 195% revenue increase in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Imprimis Pharmaceuticals reported total revenue of $2 million in the second quarter, a 195% increase from $0.7 million in the same quarter of 2014, according to a press release.

Net loss was reported at $3.7 million, or $0.39 per share, in the second quarter compared with a net loss of $2.6 million, or $0.28 per share, in the same quarter of 2014.

Sales of Tri-Moxi and Tri-Moxi-Vanc were reported at $516,000 compared with $51,000 a year ago. Sales of combination topical eye drop formulations were reported at $96,000.